Implementation of CBT-I in Cancer Clinics

Implementation of a Stepped Care Cognitive-Behavioral Therapy for Insomnia in Routine Cancer Care

Insomnia affects 30-60% of cancer patients, thus making it one of the most common disturbances in this population. When untreated, which is the rule rather than the exception, insomnia often becomes chronic. Chronic insomnia is associated with numerous negative consequences (e.g., increased risk for psychological disorders, health care costs). A large body of evidence supports the efficacy of cognitive-behavioral therapy for insomnia (CBT-I) in cancer patients, but CBT-I is still not offered routinely in cancer clinics. Self-administered CBT-I (e.g., video-based intervention) has been developed to increase patients' access to this treatment. However, results of clinical trials have suggested that these minimal treatments would be better used as a first step of a stepped care model. In stepped care, patients receive only the level of intervention they need. Generally, the entry level is a minimal, less costly, intervention (e.g., self-help intervention) followed by a more intensive form of treatment if needed (if the patient is still symptomatic). The investigators have recently assessed the efficacy of a stepped care model to administer CBT-I in cancer patients, which includes a web-based CBT-I (called Insomnet) followed by up to 3 sessions with a psychotherapist if the patient is still symptomatic. Results of this study suggest that this model of care is non-inferior to a standard face-to-face treatment (Savard, Ivers, et al., in revision), while being more cost-effective. A stepped care CBT-I could therefore be offered in routine cancer care clinics.

This project will assess the feasibility and effectiveness of implementing a stepped care CBT-I in real-world cancer clinics, using a non-randomized stepped wedge design to compare the effects of our program (active phase) with a passive phase. The program is called Insomnia in Patients with Cancer - Personalized Treatment (IMPACT). The stepped care CBT-I (active intervention) is being implemented sequentially in the four participating hospitals over a number of equally spaced time periods of 4 months (wedges), for a total of 5 time points, over a period of 20 months.

Study Overview

• Status: Recruiting
• Conditions: Insomnia
• Intervention / Treatment: Behavioral: Web-based cognitive-behavioral therapy for insomnia (CBT-I); Behavioral: Professionally-administered booster face-to-face CBT-I sessions

• Study Type: Interventional
• Enrollment (Anticipated): 120
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Josée Savard, Ph.D.; Phone Number: 20622 418-525-4444; Email: josee.savard@psy.ulaval.ca

Study Locations

• Canada
  • Québec, Canada, G1R 2J6
    • Recruiting
    • Centre de recherche de L'Hôtel-Dieu de Québec
    • Contact: Catherine Filion, M.A.; Phone Number: 20618 1-418-525-4444; Email: catherine.filion@crchudequebec.ulaval.ca
    • Principal Investigator: Josée Savard, Ph.D.
    • Sub-Investigator: Marie-Pierre Gagnon, Ph.D.
    • Sub-Investigator: Aude Caplette-Gingras, Ph.D.
    • Sub-Investigator: Lynda Bélanger, Ph.D.
    • Sub-Investigator: Charles M. Morin, Ph.D.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• have received a diagnosis of non-metastatic cancer (any type)
• to be aged 18 years and older
• to be readily able to read and understand French or English
• having the minimum cognitive abilities to read, understand and memorize information
• having access to Internet

Exclusion Criteria:

• having a psychological comorbidity needing clinical attention (e.g., major depressive disorder)
• having severe cognitive impairments (e.g., diagnosis of Parkinson's disease, dementia)
• having insomnia due to a temporary condition (e.g., acute pain, short-term medication side effects, environmental factors)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Stepped care CBT-I

Behavioral: Web-based cognitive-behavioral therapy for insomnia (CBT-I); Each week, the patients first have to read written information on the website (www.insomnet.ca), and then watch a video capsule (duration between 5 and 20 min each). Patients complete their daily sleep diary electronically on the website and the content is interactive. It includes the sending of automated emails to remind participants to complete the treatment tasks and encourage adherence, provision of tailored feedback (e.g., texts, charts) based on the information that they provide in their sleep diary, as well as quizzes with automated correction to reinforce patients' understanding of the content.; Other Names: Self-administered; Behavioral: Professionally-administered booster face-to-face CBT-I sessions; Patients who obtain an ISI score of 8 and more after completing the web-based CBT-I are "stepped up" and offered to receive up to three 50-min booster sessions of CBT-I offered individually by a psychologist (if needed). Remitted patients (good sleepers; ISI score lower than 8) will receive no further treatment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Implementation (organizational) measures	Referral, enrolment and completion rates to the stepped care CBT-I in each clinical setting.	Passive phase (4 months) vs. active phase (20 months), through study completion, an average of 24 months
1) Efficiency (patients) measures	Change in Insomnia Severity Index Scores from pre- to post-intervention. The ISI is a 7-item questionnaire designed to evaluate insomnia severity. A score greater than or equal to 8 indicates the presence of insomnia symptoms.	Pre-treatment and post-treatment (6-8 weeks later)
2) Efficiency (patients) measures	Change in daily sleep diary parameters from pre- to post-intervention: Change in sleep efficiency (SE) index (%) = Total sleep time/total time spent in bed X 100.	Pre-treatment and post-treatment (6-8 weeks later)
3) Efficiency (patients) measures	Change in daily sleep diary parameters from pre- to post-intervention: Change in sleep onset latency (SOL) = Time to sleep after lights out.	Pre-treatment and post-treatment (6-8 weeks later)
4) Efficiency (patients) measures	Change in daily sleep diary parameters from pre- to post-intervention: Change in wake after sleep onset (WASO) = Summation of nocturnal awakenings.	Pre-treatment and post-treatment (6-8 weeks later)
5) Efficiency (patients) measures	Change in daily sleep diary parameters from pre- to post-intervention: Change in total wake time (TWT) = Summation of SOL, WASO, and early morning awakening.	Pre-treatment and post-treatment (6-8 weeks later)
6) Efficiency (patients) measures	Change in daily sleep diary parameters from pre- to post-intervention: Change in total sleep time (TST) = Time in bed minus total wake time.	Pre-treatment and post-treatment (6-8 weeks later)
7) Efficiency (patients) measures	Change scores from pre to post-intervention: Hospital Anxiety and Depression Scale (HADS): A 14-item questionnaire comprising 7 items assessing depression and 7 items assessing anxiety. Scores obtained for each subscale range from 0 to 21.	Pre-treatment and post-treatment (6-8 weeks later)
8) Efficiency (patients) measures	Change scores from pre to post-intervention: Fatigue Symptom Inventory (FSI): A 14-item questionnaire measuring perceived fatigue. Each item is rated on an 11-point Likert scale, ranging from 0 to 10. A higher score indicates a higher level of fatigue or interference or a longer duration of fatigue.	Pre-treatment and post-treatment (6-8 weeks later)
9) Efficiency (patients) measures	Change scores from pre to post-intervention: The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): A 30-item questionnaire. Scores are transformed to give a score ranging from 0 to 100.	Pre-treatment and post-treatment (6-8 weeks later)
10) Efficiency (patients) measures	Change scores from pre to post-intervention: Satisfaction with Life Scale (SWLS): A 5-item questionnaire (Likert scale from 1 to 7) designed to measure global cognitive judgments of satisfaction with one's life.	Pre-treatment and post-treatment (6-8 weeks later)
1) Fidelity to the treatment protocol (psychologists)	Self-assessed adherence to the CBT-I protocol (%)	Throughout the active phase, up to 20 months
2) Fidelity to the treatment protocol (psychologists)	Perceived self-efficiency in using CBT-I protocol (%)	Throughout the active phase, up to 20 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
1) Possible predictors of a better program uptake	Clinicians and patients' demographics (e.g., age, sex)	Pre-treatment and post-treatment (6-8 weeks later) for patient; Through study completion (an average of 24 months) for clinicians
2) Possible predictors of a better program uptake	Administrators' and clinicians' attitude towards empirically-based treatments (Evidence-Based Practice Attitudes Scale (EBPAS; 15 items)): Scores obtained range from 0 to 60.	Through study completion, an average of 24 months
3) Possible predictors of a better program uptake	Stress at work (Workplace Stress Scale (WSS; 8 items)): Scores obtained range from 8 to 40.	Through study completion, an average of 24 months
4) Possible predictors of a better program uptake	Attitude towards change (Organizational Readiness for Implementing Change (ORIC; 12 items)): Participants rated the hospital's readiness for implementation on 12 items using a 5-point ordinal scale that ranged from "disagree" (1) to "agree" (5).	Through study completion, an average of 24 months
5) Possible predictors of a better program uptake	Clinicians' CBT expertise (number of years of experience with CBT)	Through study completion, an average of 24 months
6) Possible predictors of a better program uptake	Patients' familiarity with the Internet (Internet Evaluation and Utility Questionnaire (IEUQ; 15 items)): Patients respond to the questions on a 5-point likert scale from "not at all" (0) to "very" (4), with 2 open-ended items asking patients to identify "most helpful" and "least helpful" parts of the web program.	Pre-treatment and post-treatment (6-8 weeks later)
7) Possible predictors of a better program uptake	Health literacy (Brief Health Literacy Screening Tool (BRIEF; 4 items)): Each item ranges from 1 to 5 and total scores range from 4 to 20.	Pre-treatment and post-treatment (6-8 weeks later)
Possible moderating treatment effect by some of the participants' characteristics (e.g., age, sex, cancer site).		Pre-treatment (at recruitment)

Collaborators and Investigators

• Sponsor: CHU de Quebec-Universite Laval
• Collaborators: Canadian Institutes of Health Research (CIHR); Canadian Cancer Society (CCS)
• Investigators: Principal Investigator: Josée Savard, Ph.D., Centre de recherche du CHU de Québec-Université Laval

Study record dates

Study Major Dates

• Study Start (Actual): December 13, 2019
• Primary Completion (Anticipated): May 30, 2023
• Study Completion (Anticipated): May 30, 2024

Study Registration Dates

• First Submitted: March 18, 2021
• First Submitted That Met QC Criteria: March 24, 2021
• First Posted (Actual): March 26, 2021

Study Record Updates

• Last Update Posted (Actual): July 19, 2022
• Last Update Submitted That Met QC Criteria: July 18, 2022
• Last Verified: July 1, 2022

More Information

Terms related to this study

• Keywords: Web-based intervention; Cancer; Implementation; Insomnia; Cost-effectiveness; Cognitive-behavioral therapy; Stepped care model; Self-administered treatment
• Additional Relevant MeSH Terms: Mental Disorders; Nervous System Diseases; Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Sleep Initiation and Maintenance Disorders
• Other Study ID Numbers: IC118713

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No